SKYE · Skye Bioscience Inc
United States · RS rating 72 · As of 2026-11-03
| Price | 1.22 USD |
|---|---|
| 1-day change | -7.6% |
| RS rating (overall / 1M / 3M / 12M) | 72 / 13 / 97 / 36 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 22 / 56 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -12.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +45.3% |
| Market cap (USD) | $31.6M |